HIV drug resistance profile of HIV-1 CRF 01_AE protease and integrase coding regions in HIV infected Cambodian patients failing LPV-based 2nd line antiretroviral regimen
2011

HIV Drug Resistance in Cambodian Patients

Sample size: 95 publication Evidence: moderate

Author Information

Author(s): Nouhin Janin, Ngin Sopheak, Ken Sreymom, Ouk Vara, Segeral Olivier, Chea Kimlay, Phon Kerya, Delfraissy Jean-François, Nerrienet Eric

Primary Institution: Institut Pasteur du Cambodge

Hypothesis

What is the resistance pattern of protease and integrase coding regions in HIV-1 CRF01-AE infected patients failing LPV-based 2nd line regimen in Cambodia?

Conclusion

About 30% of Cambodian patients on LPV/r-based 2nd line regimen developed resistance mutations to multiple protease inhibitors.

Supporting Evidence

  • 28 out of 95 patients developed resistance mutations to multiple protease inhibitors.
  • Most patients were not naïve to protease inhibitors before starting LPV/r.
  • The study highlights the need for evaluating the efficacy of LPV/r-based regimens.

Takeaway

Some people in Cambodia who are taking a specific HIV medicine are not getting better because the virus is changing and becoming resistant to the medicine.

Methodology

Analysis of drug resistance genotyping of 95 HIV-1 strains from patients on LPV/r-based 2nd line regimen.

Limitations

The study may not represent all HIV-1 infected patients in Cambodia due to the specific cohort studied.

Participant Demographics

HIV-1 CRF01-AE infected patients in Cambodia, with a median duration on LPV/r regimen of 34.5 months.

Digital Object Identifier (DOI)

10.1186/1753-6561-5-S1-P89

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication